Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials

Publication date: Available online 10 October 2017
Source:Seminars in Oncology
Author(s): M.H.F. Poorthuis, R.W.M. Vernooij, R.J.A. van Moorselaar, Th.M. de Reijke
Treatment decision in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel are challenging. We systematically searched the published literature on all treatment options and assessed the risk of bias and quality of evidence. We found the best available evidence for effective prolongation of overall survival and progression-free survival for abiraterone acetate plus prednisone versus placebo plus prednisone and enzalutamide versus placebo. Other treatment modalities could be beneficial for individual patients by taking the selection criteria of the randomized clinical trials, the risk of bias, the subgroup analyses, and the quality of life and adverse events into consideration. Further research is needed to determine the sequence, timing and combination of different treatments.



http://ift.tt/2zey0jc